Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ventricular Ejection Fraction
Conditions
Ventricular Ejection Fraction
Trial Timeline
Jul 1, 2006 → Apr 1, 2008
NCT ID
NCT00401687About Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension is a approved stage product being developed by Lantheus Holdings for Ventricular Ejection Fraction. The current trial status is completed. This product is registered under clinical trial identifier NCT00401687. Target conditions include Ventricular Ejection Fraction.
What happened to similar drugs?
1 of 10 similar drugs in Ventricular Ejection Fraction were approved
Approved (1) Terminated (2) Active (7)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00401687 | Approved | Completed |
Competing Products
20 competing products in Ventricular Ejection Fraction